2023 Annual Business Report

2023 Outlook

In 2023, Valneva expects further product sales growth as the travel market continues to recover.

 

2023  Outlook

Our Financials & Outlook

2023 Financial Guidance

  • Expected total revenues and other income between €220 million and €260 million:
    • €130 million to €150 million of product sales, including marginal COVID-19 vaccine sales under an existing supply agreement with the Kingdom of Bahrain
    • Between €90 million and €110 million of other income
  • R&D expenses expected between €70 million and €90 million